Browse the latest research summaries in the field of immunology for spinal cord injury patients and caregivers.
Showing 201-210 of 730 results
Clinical and Translational Medicine, 2024 • April 2, 2024
Here, we identified an unreported ACOD1-p62-Nrf2-ACOD1 feedback loop exerting anti-inflammatory and anti-OS in inflammatory microglia, and demonstrated the neuroprotective role of ACOD1 after SCI, whi...
KEY FINDING: ACOD1 attenuated neuroinflammation and oxidative stress after spinal cord injury.
Not specified, 2024 • April 4, 2024
The study investigates the role of CD11b in the inflammatory response following spinal cord injury (SCI) in mice. CD11b KO mice showed increased neuroinflammation. CD11b KO mice exhibited improved loc...
KEY FINDING: Genetic deletion of CD11b increases the neuroinflammation in the injured spinal cord tissue.
Frontiers in Immunology, 2024 • April 11, 2024
This case report details an atypical presentation of GFAP-A in a 54-year-old man following SARS-CoV-2 vaccination. The patient's condition rapidly deteriorated, leading to severe unconsciousness and e...
KEY FINDING: The patient developed GFAP-A shortly after receiving the SARS-CoV-2 vaccine, suggesting a possible link between vaccination and the onset of the autoimmune condition.
Journal of Translational Autoimmunity, 2024 • April 26, 2024
This review examines the efficacy of stem cell therapy, specifically MSCs and HSCs, in treating SLE in both animal models and human patients. The findings suggest that MSC and HSC therapies can improv...
KEY FINDING: MSC and HSC therapies can improve disease activity and severity in organs affected by SLE, such as the kidney, lung, liver, and bone.
Cellular & Molecular Biology Letters, 2024 • May 6, 2024
This study investigates the role of ADAM8 in microglia-mediated neuroinflammation following spinal cord injury (SCI). The research demonstrates that ADAM8 promotes microglial activation, migration, an...
KEY FINDING: ADAM8 up-regulation in microglia is associated with inflammation after SCI.
Turkish Journal of Medical Sciences, 2023 • December 12, 2023
This study aimed to explore the therapeutic effects of ginger extract, enriched with trans-[6]-shogaol and [6]-gingerol, on neuroinflammation in the spinal cord and cortex of rats with experimental sc...
KEY FINDING: Ginger treatment significantly improved locomotor activity and reduced thermal hyperalgesia in CCI rats, indicating a positive impact on pain-related behaviors.
International Journal of Medical Sciences, 2024 • May 13, 2024
This study investigated the effects of pregabalin on microglial differentiation in a rat model of neuropathic pain induced by sciatic nerve damage. The rats were treated with either pregabalin or a co...
KEY FINDING: Pregabalin treatment significantly reduced neuronal damage in both the brain and spinal cord of neuropathic pain rats compared to the control group.
Cureus, 2024 • May 15, 2024
This report presents the unique case of a patient who developed a spinal epidural abscess and bacteremia secondary to the hematogenous spread of Bacteroides spp. from a hospital-acquired stage 4 sacra...
KEY FINDING: The patient developed a spinal epidural abscess and bacteremia secondary to the hematogenous spread of Bacteroides spp. from a hospital-acquired stage 4 sacral pressure ulcer.
CNS Neurosci Ther, 2024 • May 11, 2024
TBI and SCI involve intricate pathological mechanisms, and the inflammatory response contributes significantly to secondary injury in TBI and SCI. This study examines the upstream and downstream pathw...
KEY FINDING: This study examines the upstream and downstream pathways involved in inflammation caused by TBI and SCI, including interleukins, T cells, NK cells, XCL1, XCR1+ dendritic cells, and interferon-gamma, describing their proinflammatory effect.
PLoS ONE, 2024 • July 5, 2024
This systematic review evaluated immunosuppression strategies in stem cell trials for retinal and neural cells. It analyzed 18 articles, focusing on retinal cells, spinal cord injury, and ALS. The rev...
KEY FINDING: Multi-drug and short-term immunosuppression regimens are commonly employed in stem cell trials involving retinal and neural cells.